Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Hrithik Roshan, Ratan...

    Hrithik Roshan, Ratan Tata ready to Invest in CureFit

    Written by savita thakur thakur Published On 2017-02-28T12:17:01+05:30  |  Updated On 28 Feb 2017 12:17 PM IST
    Hrithik Roshan, Ratan Tata ready to Invest in CureFit

    BENGALURU: CureFit healthcare, a healthcare start up company may receive the investments from Ratan Tata and Bollywood actor Hrithik Roshan as the company is reported to be currently in talks with both of them with investment purpose. It is expected that the deal will be finalized in next few months.


    CureFit is a healthcare startup founded by Former executives Mukesh Bansal and Ankit Nagori of Flipkart, an online retailer giant. In the last one year, the company has raised about 20 million dollars and currently counts venture capital firms Kalaari Capital, Accel Partners and IDG Ventures as investors.


    Hrithik Roshan who worked with Bansal in Myntra for his lifestyle brand HRX, seems to be interested in picking up an equity stake in the company report ET. Giving an idea about their deal, Hrithik Said, “This partnership will mostly be a cash-plus-equity deal."


    Speaking with ET, the company officials said, motive behind this investment is to make the people fit with celebrities using similar technique in the fitness world.

    At the same, it is reported that Tata is already an angel investor in CureFit and a fresh investment from him could be a part of the new round of 15-20 million dollars, which the startup plans to raise this year, said two officials who declined to be identified.

    The officials further reported that the deals has not be finalised yet. Nagori said, "Queries sent to Tata on email did not facilitate any response. Ratan came as an angel investor right at the time when we were incorporating the company."


    CureFit began its operations last year in April. The company has raised 15 million dollars in Series A funding from Kalaari, Accel and IDG Ventures. CureFit operates as a direct seller of services rather than a marketplace. There are four companies under CureFit- CureFit Logistics, New World Inventions, CureFit Healthcare and Curefoods.


    Read also: CureFit raises $15M from Accel, IDG and Kalaari


    The new Signature workout style designed by Hrithik Roshan under his HRX brand will be launched officially next month in the startup’s gym centre, Cult.


    Recently Ratan Tata announced a collaboration with University of California to established Tata institute of active genetics and society. This complementary unit will support a collaborative research enterprise in India (TIAGS-India). The goal of the Institute is to push the boundaries of bioscience in support of human needs and society, and to build scientific capacity in India.

    Read also: Tata Trusts, University of California to establish Tata Institute for Active Genetics and Society
    Ankit NagoricurefitCureFit HealthcareFlipkartHrithik RoshanInvestmentMukesh BansalMyntraRatan Tata
    Source : With inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok